AstraZeneca (AZN) Stock: Gaining On FDA Approval


AstraZeneca plc (ADR) (NYSE:AZN) is having a good day in the market today, and it started to spike minutes ago as the FDA approved a new treatment. Of course, this led to excitement among investors, sending the stock upward and prompting our partners at Trade Ideas to alert us to the gains. At the moment (12:31), AZN is trading at $30.41 per share after a gain of $0.16 per share (0.53%) thus far today.

AZN Receives FDA Approval

As mentioned above, AstraZeneca is having a strong day in the market today following news that the FDA approved a new treatment. The treatment is durvalumab with the brand name Imfinzi. It is a checkpoint inhibitor that’s designed for the treatment of bladder cancer.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AZN. In particular, we’re interested in the next steps following the FDA approval of Imfinzi. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here